COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 6 FDA records to the applicant name Ventana Medical Systems, Inc. (Roche Tissue Diagnostics). It includes 3 original PMA approvals. 2 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 17, 2021 to Oct 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QNH appears in 3 of the 6 linked filings. The collection spans 3 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P210001, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 1910 E. Innovation Park Dr., Tucson, AZ, 85755. Recorded on P240037/S003, decision dated Oct 23, 2026.
Device categories in this collection
Immunohistochemistry Assay, Antibody, Met; Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay; Immunohistochemistry Assay, Antibody.
Changes described in PMA records
FDA approved a labeling change for the VENTANA MET (SP44) RxDx Assay under supplement S003. The change adds results from supplemental data in Post-Approval Study Report P240037/R004 concerning use of SurePath for preparation of cytology specimens.
This is a Normal 180 Day Track supplement with no user fee, classified as a Labeling Change - PAS. The decision does not represent a new approval of the assay system itself. The statement reports the purpose of the labeling update but does not independently establish safety or clinical effectiveness.
FDA approval-order wording
Approval to update the labeling for the VENTANA MET (SP44) RxDx Assay to include results of supplemental data provided in the Post-Approval Study (PAS) Report P240037/R004 for utilization of SurePath for preparation of cytology specimens.
Oct 23, 2026 · Normal 180 Day Track No User FeeThe FDA recorded approval of a supplement to PMA P210001 for the VENTANA MMR RxDx Panel, an immunohistochemistry test for DNA mismatch repair protein assay in pathology. The supplement adds a new anti-PMS2 clone, VENTANA anti-PMS2 (SP487) Rabbit Monoclonal Primary Antibody, to the panel for use on the BenchMark ULTRA and BenchMark ULTRA PLUS platforms.
This is a component change under the Normal 180 Day Track, not an approval of a new system; the P210001 identifier ties it to the original panel PMA. The entry states the reported purpose only and gives no data on analytical performance, safety or clinical effectiveness, and it does not describe any new indication.
FDA approval-order wording
Approval to add a new anti-PMS2 clone, VENTANA anti-PMS2 (SP487) Rabbit Monoclonal Primary Antibody, to the VENTANA MMR RxDx Panel for use on the BenchMark ULTRA and BenchMark ULTRA PLUS platforms
Oct 8, 2026 · Normal 180 Day TrackFDA’s recorded scope: VENTANA PTEN (SP218) RxDx Assay is a qualitative immunohistochemical (IHC) assay using rabbit monoclonal anti-PTEN, clone SP218, intended for laboratory use in the assessment of phosphatase and tensin homolog (PTEN) protein in formalin-fixed paraffin-embedded (FFPE) prostatic adenocarcinoma tissue specimens by light microscopy. The assay is for use with OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument. The assay is indicated as a companion diagnostic to aid in identifying patients who may be eligible for treatment with TRUQAP (capivasertib) in combination with abiraterone acetate in accordance with the approved therapeutic product labeling. The clinical cutoff for PTEN Loss status is >=90% of viable malignant cells with no specific cytoplasmic staining.Test results should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.This product is intended for in vitro diagnostic (IVD) use.
Jun 12, 2026FDA’s recorded scope: approval of manufacturing process changes
Jan 6, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for the VENTANA MET (SP44) RxDx Assay. The device is a qualitative immunohistochemical assay using rabbit monoclonal anti-MET, clone SP44, intended for use in the assessment of MET protein in formalin-fixed, paraffin embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) specimens by light microscopy. This assay is for use with OptiView DAB IHC Detection Kit for staining on a BenchMark ULTRA or BenchMark ULTRA PLUS instrument.MET protein expression clinical cut-off is >= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining (3+) in non-squamous NSCLC. VENTANA MET (SP44) RxDx Assay is indicated as an aid in identifying non-squamous NSCLC patients who may be eligible for treatment with EMRELIS (telisotuzumab vedotin-tllv). The results of VENTANA MET (SP44) RxDx Assay should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information and proper controls.This product is intended for in vitro diagnostic (IVD) use.
May 14, 2025Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.